What safety findings were reported regarding the combination treatment of intismeran and Keytruda?
The safety profile of the combination treatment was consistent with earlier studies and showed no new risks. Moderna president Stephen Hoge noted that the findings showed early cancers might be treated more aggressively than with prior treatments that were more toxic to the body.
Q&A ID bfee9c1c-8c76-4a78-8378-ef53f4d70596
What was the market impact on Moderna following the decline in demand for its COVID vaccine post-pandemic?
Moderna's market value plummeted more than 90% after the demand for its COVID vaccine declined following the pandemic.
Q&A ID 7b501dbf-f6e1-4b19-a600-912ae22f5071
Besides skin cancer, what other types of cancer could the customized mRNA therapy potentially be adapted for?
The customized therapy could potentially be adapted for cancers of the kidney, bladder, and pancreas.
Q&A ID 3b8fc126-1e0d-4619-9a40-16cf98f4b10c
In what combination was Moderna's intismeran therapy tested and for which specific condition?
Intismeran was tested in combination with Merck's cancer drug Keytruda in more than 1,100 patients with high-risk melanoma that had been surgically removed. The combination showed a "clinically meaningful improvement" over treating the skin cancers with Keytruda alone.
Q&A ID 675de64d-09fd-4da1-845d-74caefa4b5e8
